The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies

Chimeric antigen receptor (CAR) T cells have been successfully used in the therapy of B cell leukemia and lymphoma, but still have many challenges in their use for treating T cell malignancies, such as the lack of unique tumor antigens, their limitation of T cell expansion, and the need for third pa...

Full description

Bibliographic Details
Main Authors: Diwei Zheng, Xindong Wang, Lin Cheng, Le Qin, Zhiwu Jiang, Ruocong Zhao, Yao Li, Jingxuan Shi, Qiting Wu, Youguo Long, Suna Wang, Zhaoyang Tang, Wei Wei, Jie Yang, Yangqiu Li, Hongsheng Zhou, Qifa Liu, Pentao Liu, Xinwen Chen, Yao Yao, LiHua Yang, Peng Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Immunology
Subjects:
CCR8
TAX
ATLL
T cell malignancy
CAR T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.808347/full

Similar Items

Similar Items